These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23861604)

  • 41. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
    Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
    Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prostate cancer and Cancer Treatment-Induced Bone Loss(CTIBL)].
    Matsushima H
    Clin Calcium; 2016 Jul; 26(7):1039-45. PubMed ID: 27346316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
    Yasuda H
    Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Denosumab in osteoporosis.
    Diab DL; Watts NB
    Expert Opin Drug Saf; 2014 Feb; 13(2):247-53. PubMed ID: 24289327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
    Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
    Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases].
    Dougall W; Chaisson M
    Clin Calcium; 2006 Apr; 16(4):627- 35. PubMed ID: 16582514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.
    Doria C; Leali PT; Solla F; Maestretti G; Balsano M; Scarpa RM
    Clin Cases Miner Bone Metab; 2016; 13(3):195-199. PubMed ID: 28228781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.
    Anastasilakis AD; Toulis KA; Polyzos SA; Anastasilakis CD; Makras P
    Ther Clin Risk Manag; 2012; 8():295-306. PubMed ID: 22767993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
    Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
    Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. From bone to breast and back - the bone cytokine RANKL and breast cancer.
    Hofbauer LC; Rachner TD; Hamann C
    Breast Cancer Res; 2011 May; 13(3):107. PubMed ID: 21635706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
    Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RANKL as a target for the treatment of osteoporosis.
    Matsumoto T; Endo I
    J Bone Miner Metab; 2021 Jan; 39(1):91-105. PubMed ID: 33057808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
    Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
    Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Review on the Role of Denosumab in Fracture Prevention.
    Pang KL; Low NY; Chin KY
    Drug Des Devel Ther; 2020; 14():4029-4051. PubMed ID: 33061307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer-treatment-induced bone loss, part 1.
    Michaud LB; Goodin S
    Am J Health Syst Pharm; 2006 Mar; 63(5):419-30. PubMed ID: 16484516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.